🔗 Share this article

While the US proceeds with unprecedented adjustments to its vaccination schedules, one figure has surfaced unexpectedly: Høeg, a Danish American sports medicine doctor and public health researcher who rose to prominence by questioning Covid shots during the global health crisis and has focused upon potential deaths after Covid vaccination in her short tenure at the US Food and Drug Administration (FDA).

Scheduled Overhauls to Childhood Immunization Program

Agency leaders had intended to reveal sweeping changes to the pediatric immunization program in December, aligning the US with Denmark’s vaccine program, it is understood – a significant shift that would place the US out of step with many the global community with no evidence for improved outcomes. The announcement has been delayed until the next year.

Rather than the top vaccines chief, Tracy Beth Høeg is listed to present at the gathering. She was just designated interim head of the FDA’s Center for Drug Evaluation and Research (CDER), the fifth appointee to run the division this calendar year.

A New Direction at the Agency

This interim role could signify a strengthened alliance between the drug and vaccine divisions as Høeg and Dr. Prasad strengthen their influence at the regulatory agency – and it signals a renewed priority upon rolling back long-standing vaccines at the FDA.

Høeg has often pushed for halting some pediatric vaccine recommendations in the US so as to align more similar to Denmark's approach, a country with universal health coverage and a number of inhabitants approximately the population of Wisconsin’s.

So far public appearances, she has persisted in emphasizing on vaccines – usually the purview of Prasad, director of the FDA’s CBER – rather than drug regulation.

Questions Over Expertise

The appointee has no obvious background in drug development, approval processes or management, which has been customary for former leaders of the CBER. She has worked at the FDA as a senior adviser to the FDA chief and CBER since spring.

“It seems she lacks to have the necessary background” for leading the drug-regulation department, said a neurologist and psychiatrist. “She has not conducted a clinical trial. She has no expertise in running a sizeable institution. She lacks background in drug approvals.”

Past directors of the center would “understand laws and regulations and the science of drug development”, commented a former acting FDA commissioner. “Frankly, she doesn’t have the kind of background that former directors who headed CBER have had.”

This division has an enormous range of responsibilities at the FDA, the former commissioner pointed out.

“Many people just pays attention on the innovative therapies, but the off-patent medication office clears numerous generic medications. There’s a biologic copycat branch, over-the-counter program and other areas, and every single one must be supervised,” she explained. “The area you neglect, that is the part that I always told people is going to bite you.”

Furthermore, a significant leadership aspect to the job, which oversees over 5,000 employees. “It’s a enormous leadership role, if you execute it properly,” she concluded.

Agency Reaction and Contentious Policies

Regarding questions about Høeg’s credentials and whether this appointment signifies more teamwork among regulatory chiefs on immunizations, a representative responded that the “inquiries are based on incorrect assumptions”.

“Her resume is consistent with the responsibilities of her position,” the spokesperson said, citing the time Høeg spent guiding the agency head on “drug safety and approval science, including computerized risk analysis and immunization monitoring”.

In her interim role, Høeg assumes responsibility for the agency head's controversial priority voucher program, a controversial expedited medication authorization process that reportedly worried her predecessors. “How are these drugs being selected for this fast-track system? Who makes the choices?” Dr. Howard asked. “There is a lot of confidentiality occurring at the agency right now.”

In general, he remarked, “the FDA seems to be moving towards laxer oversight of all drugs, with the exception of immunizations.”

Documented History on Immunizations

Concerning vaccines, Dr. Høeg has a more established, if concerning, history, Howard said. She published a study using non-validated crowd-sourced reports to estimate the frequency of myocarditis after COVID-19 vaccination. She counseled the state of Florida top health official Dr. Joseph Ladapo, who allegedly have altered data to suggest COVID-19 vaccinations are riskier than they are.

Part of her “wish list” for the current federal leadership encompassed altering regulations for recently developed shots and discontinuing “unnecessary” immunizations, she remarked following the vote on a audio program. At the FDA, Høeg has according to sources floated the idea of preventing teenage boys from obtaining COVID-19 vaccines.

“She’s an all-around true believer who commences with her beliefs and reverse-engineers to retrofit the science in a extremely misleading, dishonest manner,” Howard said.

Consolidating Power and a “Campaign of Retribution”

Høeg aligned with other contrarians, {like|